Catalyst Pharmaceuticals
David Cruz, CPA has a diverse work experience spanning multiple industries. David began their career as a Semester of Discovery (SDI) Intern at PwC in 2012, followed by a role as VP of Information Technology at Beta Alpha Psi. David then worked as a File Clerk at Calvin-Giordano & Associates from 2009 to 2013. In 2013, they returned to PwC as an Assurance Intern. From 2014 to 2018, David served as a Senior Assurance Associate at PwC. In 2018, they joined Focal Point Data Risk as a Senior Consultant for a year. Currently, they serve as the Assistant Controller and Director of Financial Planning and Analysis at Catalyst Pharmaceuticals, Inc., starting in 2019.
David Cruz, CPA holds a Master's degree in Accounting from Florida International University, which they obtained in 2014. Prior to that, they earned a Bachelor of Accounting from Florida International University - College of Business in 2012. Their education journey began with an Associates in Arts degree in Business Administration from Broward College, which they completed in 2011. In addition to their education, David Cruz also holds a CPA certification from the State of Florida.
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.